Apyx Medical Corporation

Apyx Medical Corporation

2.65
USD
-0.16
(-5.69%)
-0.19EPS
103.20MMarket Cap
Mar 18Next Earn
Apyx Medical Corporation
NASDAQ:APYX
(Nasdaq Stock Market)

Recent

price

2.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
1.4
1.44
1.57
1.34
1.56
1.21
0.32
0.33
0.5
0.83
0.81
1.41
1.29
1.51
1.35
1.29
1.37
Revenue per Share
-0.09
0.01
0.03
-0.39
-1.03
0.34
-0.14
-0.16
1.89
-0.58
-0.35
-0.44
-0.67
-0.54
-0.66
-0.27
-0.19
Basic EPS, GAAP
-0.04
0.08
-0.03
-0.18
-0.06
-0.26
-0.11
-0.14
-0.64
-0.58
-0.49
-0.33
-0.62
-0.17
-0.53
-0.22
-0.2
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.24
1.26
1.3
1.08
0.08
0.87
0.85
0.67
2.59
2.09
1.86
1.56
1.09
0.77
0.38
0.35
0.23
Book Value per Share
1.06
1.13
1.17
0.96
-0.02
0.79
0.79
0.66
2.58
2.09
1.86
1.56
1.09
0.77
0.38
0.35
0.23
Tangible Book Value per Share
17
18
18
18
18
24
27
31
33
34
34
34
35
35
36
41
43
Basic Weighted Avg Shares
24
25
28
24
28
30
9
10
17
28
28
49
45
52
48
53
60
Sales/Revenue/Turnover
-6.05
3.24
3.78
-15.49
-21.13
-23.67
-129.18
-120.78
-81.51
-73.91
-72.47
-29.78
-52.94
-38.11
-39.18
-12.2
-5.5
Operating Margin (%)
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Depreciation Expense
-2
- -
1
-4
-17
-5
-4
-5
63
-20
-12
-15
-23
-19
-23
-11
-8
Net Income, GAAP
- -
- -
26.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-6.34
0.43
2.23
-18.34
-62.43
-18.19
-44.79
-49.46
377.71
-69.79
-42.93
-31.27
-52.09
-35.75
-48.78
-21.22
-14.16
Profit Margin (%)
13
14
14
17
12
18
21
17
81
64
57
48
31
58
46
47
43
Working Capital
4
3
3
3
3
3
3
3
- -
1
- -
- -
1
38
38
39
39
LT Debt
22
22
23
21
5
23
26
22
87
71
64
54
38
27
14
15
10
Total Equity
- -
- -
2.98
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
3.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-7.17
0.5
2.74
-33.15
-177.05
67.16
-15.92
-20.98
114.86
-24.88
-17.63
-25.84
-50.79
-58.22
-114.7
-77.99
-108.99
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
35
35
36
LT Finance Leases
4
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
154
189
103

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
55
53
54
Cash, Cash Equivalents & STI
31
28
26
Accounts Receivable, Net
13
14
15
Inventories
10
11
12
Total Current Liabilities
9
9
11
Payables & Accruals
8
8
10
ST Debt
- -
- -
- -
Deferred Revenue
1
1
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.56%
-23.5%
3.46%
Free Cash Flow
51.5%
31.6%
-51.44%
Net Income, GAAP
-147.41%
6.85%
-52.22%
Sales/Revenue/Turnover
16.25%
17.24%
9.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10
12
11
14
48
2025
9
11
13
19
53
2026
12
14
14
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.22
-0.19
-0.14
-0.12
-0.66
2025
-0.1
-0.09
-0.05
-0.03
-0.27
2026
-0.05
-0.07
-0.04
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Apyx Medical Corporation (Nasdaq: APYX) develops, manufactures, and markets advanced energy-based medical devices for cosmetic surgery and hospital surgical applications; its core offerings include the Renuvion helium plasma technology platform for precise tissue contraction and coagulation in cosmetic procedures, the J-Plasma system for surgical tissue dissection in hospital settings, and the AYON Body Contouring System, which integrates fat removal, closed-loop contouring, tissue contraction, and electrosurgical capabilities. The company operates through two primary segments, Advanced Energy and Original Equipment Manufacturer (OEM), with the OEM segment providing custom generators, handpieces, helium gas supplies, and related accessories to other medical device manufacturers and startups via strategic agreements. Apyx Medical also maintains manufacturing facilities in Clearwater, Florida, and Bulgaria to support its European operations and service center. Founded in 1982 and headquartered at 5115 Ulmerton Road in Clearwater, Florida, the company--formerly known as Bovie Medical--targets plastic surgeons, facial plastic surgeons, cosmetic physicians, and hospital surgical teams primarily in the United States, with expanding international presence including a recent launch of Renuvion in China. In November 2025, Apyx Medical priced a $10 million public offering of common stock underwritten by Lucid Capital Markets to bolster its growth initiatives; the company supports its products with over 90 clinical documents and continues to innovate in helium plasma technology for minimally invasive procedures.

Company News

  • Apyx Medical Corporation (APYX) Presents at 2026 UBS Global Healthcare Conference Transcript

  • Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript

  • Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates

  • Apyx Medical Q3 Earnings Call Highlights

  • Apyx Medical Corporation Reports Third Quarter 2026 Financial Results

  • SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)

  • Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

  • Apyx Medical Corporation to Participate in Upcoming Investor Conferences

  • Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality

  • Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

  • Apyx Medical Corporation (NASDAQ:APYX) Receives $6.60 Consensus Target Price from Brokerages

  • Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

  • Apyx Medical Q2 Earnings Call Highlights

  • Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

  • Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

  • Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

  • Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway

  • New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®

  • Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction

  • Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™